Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
Natasha Atanaskova Mesinkovska, Dalia Wajsbrot, Rodney Sinclair, Ernest H. Law et al.
Citations
4 citations
Journal
American Journal of Clinical Dermatology
Topics
Hair Growth and Disorders
Field-Weighted Citation Impact (FWCI)
2.14
article
Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
Natasha Atanaskova Mesinkovska, Dalia Wajsbrot, Rodney Sinclair, Ernest H. Law, Debanjali Mitra, Robert A. Wolk, Brett King
article en
4 citations
Abstract
No abstract available for this paper.
Publication Tag
American Journal of Clinical DermatologyVol. 26(1)
Institutions
Pfizer (United States) (US), Yale University (US), UC Irvine Health (US), Sinclair Dermatology (AU)